Kepler Capital Sticks to Their Buy Rating for Atrys Health SA (A2T)
Kepler Capital analyst Julian Megias maintained a Buy rating on Atrys Health SA (A2T – Research Report) on June 10 and set a price target of €5.00. The company's shares closed last Tuesday at €2.57.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Megias is a 2-star analyst with an average return of 2.4% and a 62.50% success rate.
Currently, the analyst consensus on Atrys Health SA is a Moderate Buy with an average price target of €5.00.
The company has a one-year high of €4.08 and a one-year low of €2.28. Currently, Atrys Health SA has an average volume of 723.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
William Blair Sticks to Its Buy Rating for RH (RH)
William Blair analyst Phillip Blee maintained a Buy rating on RH (RH – Research Report) today. The company's shares closed today at $189.12. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Blee covers the Consumer Cyclical sector, focusing on stocks such as RH, Costco, and Traeger. According to TipRanks, Blee has an average return of 7.1% and a 55.00% success rate on recommended stocks. Currently, the analyst consensus on RH is a Moderate Buy with an average price target of $268.47, which is a 41.96% upside from current levels. In a report released today, Wells Fargo also maintained a Buy rating on the stock with a $275.00 price target. Based on RH's latest earnings release for the quarter ending February 1, the company reported a quarterly revenue of $812.41 million and a net profit of $13.92 million. In comparison, last year the company earned a revenue of $738.26 million and had a net profit of $11.38 million
Business Insider
31 minutes ago
- Business Insider
Stock Market News Review: SPY, QQQ Drop amid Israel-Iran Escalation, VIX Surge
Both the S&P 500 (SPX) and the Nasdaq 100 (NDX) closed the Friday trading session down by over 1% as the Israel-Iran conflict has escalated with Iran striking back at Israel. Rising geopolitical uncertainty benefits the Volatility Index (VIX), which finished with a sharp 19.7% jump. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter This morning, President Trump said that Israel's attack on Iran could actually benefit the market. 'I think ultimately, it would be great for the market because Iran will not have a nuclear weapon,' said Trump in an interview with the Wall Street Journal. 'It will be great for the market —should be the greatest thing ever for the market. Iran won't have a nuclear weapon that was a great threat to humanity.' On Truth Social, Trump urged Iran to sign a deal that would end its nuclear program. Crude oil futures jumped by about 7% today as the conflict threatens disruptions to the Strait of Hormuz, which acts as a passage for nearly 20% of global oil shipments. To increase domestic production, Trump wants U.S. oil refiners to blend an all-time high of 24.02 billion gallons of biofuel into conventional fuels in 2026. Biofuels are an alternative to fossil fuels that are created from organic matter, like algae and crops. Meanwhile, consumer sentiment is on the rise, erasing six months of consecutive drops. The University of Michigan's preliminary June Index of Consumer Sentiment tallied in at 60.5, beating the estimate for 53.5 and rising from 52.2 in May. Year-ahead and long-run inflation expectations also fell. Still, consumers remain worried about the stock market, the labor market, and business conditions, with confidence levels in these areas well below where they were six months ago. On the trade front, UK Prime Minister Keir Starmer said that the U.S. and UK have made progress in reaching a final trade deal, saying 'There's nothing unexpected in the implementation, and so we haven't got any hiccups or obstacles.' The S&P 500 ended the week with a 0.41% loss while the Nasdaq 100 fell by 0.57%.
Business Insider
31 minutes ago
- Business Insider
Positive Report for DocMorris (DOCM) from Octavian AG
DocMorris (DOCM – Research Report) received a Buy rating and a CHF20.00 price target from Octavian AG analyst today. The company's shares closed today at CHF7.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DocMorris with a CHF18.48 average price target, a 164.19% upside from current levels. In a report released on June 4, Jefferies also maintained a Buy rating on the stock with a CHF15.00 price target. The company has a one-year high of CHF31.02 and a one-year low of CHF6.52. Currently, DocMorris has an average volume of 409.1K.
